DALPICICLIB ISETIONATE
EGFR-TKI Resistant Mutation
Tianjin Medical University Cancer Institute and HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the EGFR-TKI Resistant Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Osimertinib Tianjin Medical University Cancer Institute and Hospital | Phase 3 | BB |
AZD9291 Shandong Cancer Hospital and Institute | Phase 3 | B |
Silevertinib Black Diamond Therapeutics, Inc. | Phase 1/2 | CC |
Nintedanib China Medical University Hospital | Phase 1/2 | CC |
Gefetinib China Medical University Hospital | Phase 1/2 | CC |
Same molecule, other indications
DALPICICLIB ISETIONATE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →